

# **CureVac: Second Interim Analysis of Pivotal Phase 2b/3 HERALD Study**

June 17, 2021

## Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the "company") contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company's opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at [www.sec.gov](http://www.sec.gov).

Franz-Werner Haas

Study Introduction

Chief Executive Officer

Ulrike Gnad-Vogt

Interim Analysis Data

Interim Chief Development Officer

Mariola Fotin-Mleczek

Second-Generation Update

Chief Technology Officer


Pierre Kemula

Q&A Availability

Chief Financial Officer



# The HERALD Study: Key Data from Second Interim Analysis



## PRIMARY OBJECTIVE

**47%**


**Efficacy** of CVnCoV in the  
**prevention** of COVID-19 cases  
of **any severity**

## PRIMARY ENDPOINT


**134 cases**

**First episodes** of virologically-  
confirmed cases of COVID-19  
of **any severity**

# The HERALD Study: Geographically Diverse and Multi-Variant





# The HERALD Study: Sequencing Efforts Define Basis for Efficacy Calculation






# COVID-19 Reality: Variants of Concern Spreading in Europe and Latin America



■ Countries where Phase 2b/3 trial is conducted


# High Variant Diversity Defines Basis for Efficacy in Second Interim Analysis






# High Variant Diversity in Overall Study Reflect New COVID-19 Reality

- B.1 (wild type)
- B.1.1 (wild type)
- B.1.1.1 (wild type)
- B.1.1.10 (wild type)
- B.1.1.7 (Alpha)
- B.1.351 (Beta)
- B.1.429 (Epsilon)
- B.1.617.2 (Delta)
- P.1 (Gamma)
- A.2.5
- B.1.1.348
- B.1.1.519 (Mexico)
- B.1.111
- B.1.160
- B.1.177
- B.1.1.177.43
- B.1.1.177.53
- B.1.1.177.73
- B.1.236
- B.1.280
- B.1.526
- B.1.621 (Colombia)
- B.1.623
- C.11
- C.36
- C.37 (Peru)
- N.5
- P.1.2
- P.2




## INTERIM ANALYSIS EFFICACY




**Efficacy** of CVnCoV in the **prevention** of  
COVID-19 cases of **any severity** across **all strains**

# Reactogenicity Data on First 2,000 Vaccinated Trial Participants

## SYSTEMIC SYMPTOMS



## LOCAL SYMPTOMS



# The HERALD Study: Key Messages and Next Steps



Interim efficacy of first-generation vaccine candidate, CVnCoV, evaluated in most challenging **variant-dominated** environment



Interim efficacy of 47% against **any severity** of disease shows trend for age and strain related efficacy




Moving toward **final analysis** within 2-3 weeks on the basis of >200 cases to confirm age and strain related trends and also look at disease severity




Full commitment to proceed appropriate **regulatory** pathway for the most appropriate regulatory pathway.



# Second-Generation Vaccines: New Backbone for Advanced Characteristics




## Protein expression



## Preclinical Non-Human Primate (NHP) Model\*

Neutralizing antibodies, Pseudovirus assay



- CV2CoV, **faster onset** of neutralizing antibody production. 211 titer two weeks after first dose
- CV2CoV, **10-times higher** neutralizing antibody induction of CV2CoV compared to CVnCoV at peak level after 6 weeks
- Two-dose vaccination schedule of a **12µg dose** on day 0 and day 28





**Thank you for your  
attention**

CureVac  
[www.curevac.com](http://www.curevac.com)